Ageing is the single greatest risk factor for virtually every chronic disease that plagues modern society — from cardiovascular disease and cancer to neurodegeneration and metabolic dysfunction. As Australia’s population ages rapidly, with the number of Australians over 65 projected to double by 2057, the quest to understand and potentially slow the ageing process has never been more urgent or more relevant.
Anti-ageing peptides represent a cutting-edge approach to longevity research, targeting the fundamental biological mechanisms that drive cellular ageing. Unlike cosmetic anti-ageing products that address surface-level symptoms, these peptides work at the molecular level — influencing mitochondrial function, telomere maintenance, gene expression, and cellular senescence.
In this guide, we explore two of the most promising anti-ageing peptides available for research in Australia: MOTS-c and Epitalon. These remarkable compounds target different but complementary aspects of the ageing process, offering researchers powerful tools for investigating the biology of longevity.
Before examining individual peptides, it’s essential to understand the biological framework that defines ageing research. In 2013, a landmark paper published in Cell identified nine hallmarks of ageing: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication.
Anti-ageing peptides are remarkable because they can target multiple hallmarks simultaneously. MOTS-c primarily addresses mitochondrial dysfunction and deregulated nutrient sensing, while Epitalon targets telomere attrition and epigenetic alterations. Together, they provide a multi-pronged approach to ageing research that addresses several of the fundamental drivers of biological ageing.
MOTS-c (10mg) is a groundbreaking mitochondrial-derived peptide (MDP) that has revolutionised our understanding of mitochondrial signalling and its role in ageing. Discovered in 2015 by researchers at the University of Southern California, MOTS-c is encoded within the mitochondrial genome — specifically within the 12S rRNA gene — making it one of only a handful of known mitochondrial-encoded signalling peptides.
MOTS-c functions as a mitochondrial retrograde signal, communicating the metabolic status of mitochondria to the nuclear genome. Its primary mechanism involves activation of the AMPK (AMP-activated protein kinase) pathway, often called the body’s “metabolic master switch.” AMPK activation triggers a cascade of beneficial metabolic effects, including enhanced glucose uptake, improved fatty acid oxidation, increased mitochondrial biogenesis, and activation of cellular stress response pathways.
Research published in Cell Metabolism demonstrated that MOTS-c can translocate to the nucleus in response to metabolic stress, where it directly regulates gene expression by interacting with antioxidant response elements (AREs). This nuclear translocation represents a novel form of mito-nuclear communication that has profound implications for our understanding of cellular ageing.
MOTS-c research has produced remarkable findings across multiple domains of ageing biology. In metabolic research, studies have shown that MOTS-c administration can improve insulin sensitivity, reduce diet-induced obesity, and enhance exercise capacity in animal models. A study published in Nature Communications demonstrated that MOTS-c levels decline with age in humans, and that exercise — one of the most potent anti-ageing interventions known — increases circulating MOTS-c levels.
In ageing research specifically, MOTS-c has shown the ability to improve physical performance in aged mice, enhance stress resistance, and modulate the inflammatory response associated with ageing (often termed “inflammageing”). These findings suggest that MOTS-c may function as an exercise mimetic — a compound that can replicate some of the beneficial effects of physical activity at the molecular level.
For Australian researchers, MOTS-c’s metabolic effects are particularly relevant given the country’s high rates of type 2 diabetes and metabolic syndrome. The peptide’s ability to improve glucose homeostasis through AMPK activation offers a novel research avenue for addressing these conditions, which disproportionately affect Indigenous Australians and older adults.
MOTS-c has also shown promise in osteoporosis research. Studies have demonstrated that the peptide can promote osteoblast differentiation and inhibit osteoclast formation, suggesting potential applications in bone health — a critical concern for Australia’s ageing population, where osteoporosis affects approximately 1.2 million people.
Epitalon (10mg) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the natural peptide epithalamin, which is produced by the pineal gland. Developed by Russian gerontologist Professor Vladimir Khavinson, Epitalon has been the subject of over 30 years of research into its anti-ageing and life-extending properties.
Epitalon’s primary anti-ageing mechanism involves the activation of telomerase — the enzyme responsible for maintaining telomere length. Telomeres are the protective caps at the ends of chromosomes that shorten with each cell division, eventually triggering cellular senescence (permanent growth arrest) when they become critically short. By activating telomerase, Epitalon can extend telomere length, effectively resetting the cellular ageing clock.
Research published in the Bulletin of Experimental Biology and Medicine demonstrated that Epitalon treatment increased telomerase activity in human somatic cells, leading to telomere elongation and extended replicative lifespan. This finding is significant because telomere shortening is considered one of the primary hallmarks of ageing, and interventions that can maintain telomere length have the potential to delay or reverse aspects of cellular ageing.
Epitalon research spans several decades and encompasses a wide range of ageing-related outcomes. In animal studies, Epitalon administration has been associated with increased lifespan, improved immune function, normalised circadian rhythms, and enhanced antioxidant defence systems. A comprehensive review published in Neuroendocrinology Letters documented Epitalon’s ability to restore melatonin production in aged animals, normalise cortisol rhythms, and improve immune cell function.
The peptide’s effects on melatonin production are particularly noteworthy. Melatonin is a powerful antioxidant and circadian rhythm regulator that declines significantly with age. By restoring melatonin synthesis through pineal gland stimulation, Epitalon may address multiple aspects of ageing simultaneously — from sleep quality and immune function to oxidative stress and hormonal balance.
In cancer research, Epitalon has shown intriguing anti-tumour properties. Studies have demonstrated that the peptide can inhibit the growth of certain cancer cell lines while simultaneously enhancing immune surveillance — a dual effect that has significant implications for age-related cancer research. Given that cancer risk increases dramatically with age, and that Australia has one of the highest cancer rates in the world, these findings are particularly relevant to the Australian research community.
Epitalon has also been studied for its effects on retinal health. Research has shown that the peptide can protect retinal cells from age-related degeneration, with potential implications for conditions like age-related macular degeneration (AMD) — the leading cause of blindness in Australians over 50.
While MOTS-c and Epitalon target different aspects of the ageing process, their mechanisms are highly complementary. MOTS-c addresses the metabolic and mitochondrial dimensions of ageing — improving energy production, enhancing stress resistance, and optimising nutrient sensing. Epitalon, meanwhile, targets the genomic dimension — maintaining telomere length, restoring hormonal rhythms, and enhancing immune function.
Together, these peptides address at least four of the nine hallmarks of ageing: mitochondrial dysfunction (MOTS-c), deregulated nutrient sensing (MOTS-c), telomere attrition (Epitalon), and altered intercellular communication (both). This multi-hallmark approach represents the cutting edge of longevity research, where scientists increasingly recognise that effective anti-ageing interventions must target multiple biological pathways simultaneously.
Australia is home to several world-class ageing research centres, including the UNSW Ageing Futures Institute and the Centre for Healthy Brain Ageing (CHeBA) at the University of New South Wales. These institutions are at the forefront of investigating the biological mechanisms of ageing and developing interventions to promote healthy longevity.
The Australian government has recognised the importance of ageing research, with the NHMRC funding numerous studies on age-related conditions and longevity interventions. As the population ages, the economic and social imperative to find effective anti-ageing strategies will only intensify, making peptide-based longevity research an increasingly important field.
Researchers interested in related areas may want to explore our GHK-Cu copper peptide, which has demonstrated significant anti-ageing effects through gene expression modulation, or our cognitive peptides, which address the neurological dimensions of ageing.
Anti-ageing peptides represent one of the most exciting frontiers in biomedical research, offering the potential to not just treat age-related diseases but to address the fundamental biology of ageing itself. MOTS-c‘s mitochondrial magic and Epitalon‘s telomere-protecting properties provide Australian researchers with powerful tools for investigating the mechanisms of ageing and developing interventions that could extend healthy lifespan.
As our understanding of ageing biology deepens, the potential applications of these peptides will only expand. Explore our complete range of anti-ageing and longevity peptides and join the quest to unlock the secrets of healthy ageing.
Australia’s leading supplier of high-purity research peptides. Committed to scientific excellence and fast, secure domestic distribution.
Research Disclaimer: All products sold by Aus Bio Peps are strictly for laboratory research and development purposes only. These products are not for human consumption, medical, or diagnostic use. Please consult the TGA guidelines regarding research chemicals.
© 2026 Aus Bio Peps. All Rights Reserved. Based in Australia.
